ResearcherJichi Medical UniversityActive in the last 2 years
Hirofumi Fujii
Matched on ORCID iD 0000-0001-5470-5151; OpenAlex author ID A5029696370. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 31
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers
Papers 5
- αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine. Last author DOI 10.1371/journal.pone.0310984↗
- Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/pharmaceutics17010009↗
- Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
- Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
- In vivo SPECT imaging with 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model. Co-author DOI 10.2967/jnumed.111.099630↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mitsuyoshi Yoshimoto · 3 shared papers, 2012–2024 · strength 0.52
- Paper αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encap… DOI 10.1371/journal.pone.0310984↗
- Paper Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Du… DOI 10.3390/pharmaceutics17010009↗
- Paper In vivo SPECT imaging with 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis… DOI 10.2967/jnumed.111.099630↗
- Motohiro Kojima · 1 shared paper, 2024 · strength 0.21
- Akira Fukutomi · 1 shared paper, 2019 · strength 0.08
- Kentaro Sudo · 1 shared paper, 2019 · strength 0.08
- Hiromichi Shirasu · 1 shared paper, 2019 · strength 0.08
- Keiko Kamei · 1 shared paper, 2019 · strength 0.08
- Nobumasa Mizuno · 1 shared paper, 2019 · strength 0.08
- Satoshi Kobayashi · 1 shared paper, 2019 · strength 0.08
- Naohiro Okano · 1 shared paper, 2019 · strength 0.08
- Hideyuki Hayashi · 1 shared paper, 2019 · strength 0.08
- Masato Ozaka · 1 shared paper, 2019 · strength 0.08
- Akiko Todaka · 1 shared paper, 2019 · strength 0.08
- Noritoshi Kobayashi · 1 shared paper, 2019 · strength 0.08
- Shoji Nakamori · 1 shared paper, 2017 · strength 0.05
- Shinichi Ohkawa · 1 shared paper, 2017 · strength 0.05
- Taketo Yamaguchi · 1 shared paper, 2017 · strength 0.05
- Takashi Hatori · 1 shared paper, 2017 · strength 0.05
- Tatsuya Ioka · 1 shared paper, 2017 · strength 0.05
- Shinichi Egawa · 1 shared paper, 2017 · strength 0.05
- Narikazu Boku · 1 shared paper, 2017 · strength 0.05
- Yasuo Hamamoto · 1 shared paper, 2017 · strength 0.05
- Ann‐Lii Cheng · 1 shared paper, 2017 · strength 0.05
- Akihiro Funakoshi · 1 shared paper, 2017 · strength 0.05
- Junji Furuse · 1 shared paper, 2017 · strength 0.05
- Yasuo Ohashi · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.